Condition: Advanced Solid Tumor · Sponsor: BioNTech SE
The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with pumitamig (also known as BNT327 or PM8002) as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.
This description comes directly from the study's public registry record.
: BioNTech clinical trials patient information · +49 6131 9084 · patients@biontech.de
Always discuss trial participation with your own doctor first.
| Cancer Research SA | Adelaide, Australia | Recruiting |
| Monash Medical Centre | Clayton, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Australia | Recruiting |
| One Clinical Research | Nedlands, Australia | Not Yet Recruiting |
| Scientia Clinical Research Limited | Randwick, Australia | Recruiting |
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| Anhui Provincial Hospital | Hefei, China | Recruiting |
| First Affiliated Hospital of Xinxiang Medical University | Henan, China | Recruiting |
| Hunan Province Cancer Hospital | Hunan, China | Not Yet Recruiting |
| Shandong University-Jinan Central Hospital | Shandong, China | Recruiting |
| Qilu Hospital of Shandong University' | Shandong, China | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07147348